✦ LIBER ✦

MP-16.20: Thalidomide in combination with interleukin-2 for patients with metastatic renal cell carcinoma refractory to prior IL-2 and alpha-interferon treatment

✍ Scribed by R. Shiroki; S. Mori; S. Miyakawa; M. Ichino; M. Hirano; M. Kusaka; K. Hayakawa; K. Ishikawa; K. Hoshinaga

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II study of thalidomide in combi

✍ Robert J. Amato; Margaret Morgan; Anish Rawat 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Subcutaneous low-dose recombinant interl

✍ Gaston, R; Oskam, R; Philip, T; Ravaud, A; Négrier, S; Cany, L; Merrouche, Y; Le 📂 Article 📅 1994 🏛 Nature Publishing Group 🌐 English ⚖ 876 KB

5- fluorouracil blocks T-cell activity d

✍ K. Rohrmann; R. Oberneder; H. Pohla; A. Hofstetter; M. Siebels 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 206 KB

470 Original regimen of subcutaneous int

✍ B. Escudier; J.F. Rossi; A. Ravaud; J. Savary; K. Pignard; S. Négrier 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 163 KB

117 POSTER Activity of MVA 5T4 alone or

✍ R. Amato; A. Gary; A. Cao; J. Willis; M. McDonald; S. Naylor; R. Harrop; W. Shin 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Protracted venous infusion 5-fluorouraci

✍ MJ Allen; M Vaughan; A Webb; S Johnston; P Savage; T Eisen; S Bates; J Morre; R 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 66 KB